// App-Quantinova.ai

: Orally Inhaled Flecainide for the Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm Final Results From the Phase 2 Instant Trial

Researchers

Presenter

  • Alan J Camm

Principal Investigators

  • Harry Crijns

  • Arif Elvan

  • Ype Tuininga

  • Erik Badings

  • Aaf Kuijper

  • Jonas de Jong

  • Mark Lee

  • Dirk Schellings

  • Isabelle C Van Gelder

  • Jeremy N Ruskin

  • Peter R Kowey

  • Christopher Dufton

  • Jean Maupas

  • Luiz Belardinelli

Medical Centers

  • MASS GENERAL HOSPITAL, Boston, MA

  • Deventer Hospital, Deventer, Netherlands

  • Long Beach, CA

  • LANKENAU MEDICAL CENTER, Wynnewood, PA

  • InCarda Therapeutics, CA

  • InCarda Therapeutics Inc., Newark, CA

  • Maastricht Univ Med Ctr, Meerssen

  • Univ Med Cntr Groningen, Groningen

  • St George's, University of London, London, United Kingdom

Locations

  • Netherlands

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Arrhythmia

Biomarkers

  • N/A

Drug/Treatment

  • Flecainide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved